AAAAAA

   
Results: 1-25 |
Results: 25
Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in a sample of white women from Belgium
Authors: Ben Sedrine, W Devogelaer, JP Kaufman, JM Goemaere, S Depresseux, G Zegels, B Deroisy, R Reginster, JY
Citation: W. Ben Sedrine et al., Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in a sample of white women from Belgium, BONE, 29(4), 2001, pp. 374-380
Inhomogeneity of human vertebral cancellous bone: Systematic density and structure patterns inside the vertebral body
Authors: Banse, X Devogelaer, JP Munting, E Delloye, C Cornu, O Grynpas, M
Citation: X. Banse et al., Inhomogeneity of human vertebral cancellous bone: Systematic density and structure patterns inside the vertebral body, BONE, 28(5), 2001, pp. 563-571
Primary prevention of gluccocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone
Authors: Boutsen, Y Jamart, J Esselinckx, W Devogelaer, JP
Citation: Y. Boutsen et al., Primary prevention of gluccocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone, J BONE MIN, 16(1), 2001, pp. 104-112
Incidentaloma, glucocorticoid excess and low bone mineral density: a coincidence?
Authors: Devogelaer, JP
Citation: Jp. Devogelaer, Incidentaloma, glucocorticoid excess and low bone mineral density: a coincidence?, EUR J ENDOC, 145(3), 2001, pp. 237-239
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy
Authors: Reid, DM Adami, S Devogelaer, JP Chines, AA
Citation: Dm. Reid et al., Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy, CALCIF TIS, 69(4), 2001, pp. 242-247
Ipriflavone in the treatment of postmenopausal osteoporosis - A randomizedcontrolled trial
Authors: Alexandersen, P Toussaint, A Christiansen, C Devogelaer, JP Roux, C Fechtenbaum, J Gennari, C Reginster, JY
Citation: P. Alexandersen et al., Ipriflavone in the treatment of postmenopausal osteoporosis - A randomizedcontrolled trial, J AM MED A, 285(11), 2001, pp. 1482-1488
Bone mass evolution after renal transplantation
Authors: Goffin, E Devogelaer, JP Depresseux, G de Strihou, CV
Citation: E. Goffin et al., Bone mass evolution after renal transplantation, KIDNEY INT, 59(4), 2001, pp. 1594-1595
Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine
Authors: Jardinet, D Lefebvre, C Depresseux, G Lambert, M Devogelaer, JP Houssiau, FA
Citation: D. Jardinet et al., Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine, RHEUMATOLOG, 39(4), 2000, pp. 389-392
Treatment of bone diseases with bisphosphonates, excluding osteoporosis
Authors: Devogelaer, JP
Citation: Jp. Devogelaer, Treatment of bone diseases with bisphosphonates, excluding osteoporosis, CURR OP RH, 12(4), 2000, pp. 331-335
Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients
Authors: Eastell, R Devogelaer, JP Peel, NFA Chines, AA Bax, DE Sacco-Gibson, N de Deuxchaisnes, CN Russell, RGG
Citation: R. Eastell et al., Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients, OSTEOPOR IN, 11(4), 2000, pp. 331-337
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial
Authors: Reid, DM Hughes, RA Laan, RFJM Sacco-Gibson, NA Wenderoth, DH Adami, S Eusebio, RA Devogelaer, JP
Citation: Dm. Reid et al., Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial, J BONE MIN, 15(6), 2000, pp. 1006-1013
Do estrogens effectively prevent osteoporosis-related fractures?
Authors: Reginster, JY Bruyere, O Audran, M Avouac, B Body, JJ Bouvenot, G Brandi, ML Gennari, C Kaufman, JM Lemmel, EM Vanhaelst, L Weryha, G Devogelaer, JP
Citation: Jy. Reginster et al., Do estrogens effectively prevent osteoporosis-related fractures?, CALCIF TIS, 67(3), 2000, pp. 191-194
Bone mineral density in posttransplantation patients: Effects of physical activity
Authors: Cordier, P Decruynaere, C Devogelaer, JP
Citation: P. Cordier et al., Bone mineral density in posttransplantation patients: Effects of physical activity, TRANSPLAN P, 32(2), 2000, pp. 411-414
Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage
Authors: Blot, L Marcelis, A Devogelaer, JP Manicourt, DH
Citation: L. Blot et al., Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage, BR J PHARM, 131(7), 2000, pp. 1413-1421
Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen andcartilage aggrecan in rheumatoid arthritis but not in osteoarthritis
Authors: Manicourt, DH Poilvache, P van Egeren, A Devogelaer, JP Lenz, ME Thonar, EJMA
Citation: Dh. Manicourt et al., Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen andcartilage aggrecan in rheumatoid arthritis but not in osteoarthritis, ARTH RHEUM, 43(2), 2000, pp. 281-288
Background for studies on the treatment of male osteoporosis: state of theart
Authors: Kaufman, JM Johnell, O Abadie, E Adami, S Audran, M Avouac, B Ben Sedrine, W Calvo, G Devogelaer, JP Fuchs, V Kreutz, G Nilsson, P Pols, H Ringe, J Van Haelst, L Reginster, JY
Citation: Jm. Kaufman et al., Background for studies on the treatment of male osteoporosis: state of theart, ANN RHEUM D, 59(10), 2000, pp. 765-772
Evaluation of glucocorticoid replacement therapy and of their effects on bone mineral density in Addison's disease
Authors: Heureux, F Maiter, D Boutsen, Y Devogelaer, JP Jamart, J Donckier, J
Citation: F. Heureux et al., Evaluation of glucocorticoid replacement therapy and of their effects on bone mineral density in Addison's disease, ANN ENDOCR, 61(3), 2000, pp. 179-183
Osteophytes and osteoarthritis progression. Effects of nonsteroidal antiinflammatory drugs
Authors: Devogelaer, JP Manicourt, DH
Citation: Jp. Devogelaer et Dh. Manicourt, Osteophytes and osteoarthritis progression. Effects of nonsteroidal antiinflammatory drugs, OSTEO CART, 7(3), 1999, pp. 336-337
Clinical significance of antiproteinase 3 antibody positivity in cANCA-positive patients
Authors: van Pesch, V Jadoul, M Lefebvre, C Lauwerys, BR Tomasi, JP Devogelaer, JP Houssiau, FA
Citation: V. Van Pesch et al., Clinical significance of antiproteinase 3 antibody positivity in cANCA-positive patients, CLIN RHEUMA, 18(4), 1999, pp. 279-282
Functional outcome of myositis patients: Can a low-dose glucocorticoid regimen achieve good functional results?
Authors: Nzeusseu, A Brion, F Lefebvre, C Knoops, P Devogelaer, JP Houssiau, FA
Citation: A. Nzeusseu et al., Functional outcome of myositis patients: Can a low-dose glucocorticoid regimen achieve good functional results?, CLIN EXP RH, 17(4), 1999, pp. 441-446
Recommendations for the registration of drugs intended for use in the treatment of male osteoporosis
Authors: Kaufman, JM Compston, J Audran, MA Avouac, B Devogelaer, JP Lemmel, EM Vanhaelst, L Reginster, JY
Citation: Jm. Kaufman et al., Recommendations for the registration of drugs intended for use in the treatment of male osteoporosis, CALCIF TIS, 65(1), 1999, pp. 4-7
Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably inrheumatoid arthritis patients who have begun activity after a night of bedrest
Authors: Manicourt, DH Poilvache, P Nzeusseu, A van Egeren, A Devogelaer, JP Lenz, ME Thonar, EJMA
Citation: Dh. Manicourt et al., Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably inrheumatoid arthritis patients who have begun activity after a night of bedrest, ARTH RHEUM, 42(9), 1999, pp. 1861-1869
Fat conversion of femoral marrow in glucocorticoid-treated patients - A cross-sectional and longitudinal study with magnetic resonance imaging
Authors: Vande Berg, BC Malghem, J Lecouvet, FE Devogelaer, JP Maldague, B Houssiau, FA
Citation: Bc. Vande Berg et al., Fat conversion of femoral marrow in glucocorticoid-treated patients - A cross-sectional and longitudinal study with magnetic resonance imaging, ARTH RHEUM, 42(7), 1999, pp. 1405-1411
Treatment with calcitonin suppresses the responses of bone, cartilage, andsynovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions
Authors: Manicourt, DH Altman, RD Williams, JM Devogelaer, JP Druetz-Van Egeren, A Lenz, ME Pietryla, D Thonar, EJMA
Citation: Dh. Manicourt et al., Treatment with calcitonin suppresses the responses of bone, cartilage, andsynovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions, ARTH RHEUM, 42(6), 1999, pp. 1159-1167
Glomerular thrombosis: An unusual cause of renal failure in systemic lupuserythematosus
Authors: Uwonkunda, MR Cosyns, JP Devogelaer, JP Houssiau, FA
Citation: Mr. Uwonkunda et al., Glomerular thrombosis: An unusual cause of renal failure in systemic lupuserythematosus, ACT CLIN B, 53(6), 1998, pp. 371-373
Risultati: 1-25 |